{rfName}
An

Indexed in

License and use

Icono OpenAccess

Citations

33

Altmetrics

Analysis of institutional authors

De Sanjose Llongueras, SilviaAuthorRobles, CCorresponding AuthorCasabonne, DAuthorGonzalez-Barca, EAuthorBenavente, YAuthor

Share

April 6, 2015
Publications
>
Article
Sí

Antibody Response to Merkel Cell Polyomavirus Associated with Incident Lymphoma in the Epilymph Case-Control Study in Spain

Publicated to:Cancer Epidemiology Biomarkers & Prevention. 21 (9): 1592-1598 - 2012-09-01 21(9), DOI: 10.1158/1055-9965.EPI-11-1140

Authors: Robles, C; Poloczek, A; Casabonne, D; Gonzalez-Barca, E; Bosch, R; Benavente, Y; Viscidi, RP; de Sanjos, S

Affiliations

Cancer Epidemiology Research Programme, Catalan Institute of Oncology, 08908 l'Hospitalet de Llobregat, Avda. Gran Via 199-203, Barcelona, Spain - Author
CIBER de Epidemiologia y Salud Publica (CIBERESP), Spain - Author
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain - Author
Department of Pediatrics, Johns Hopkins University, School of Medicine, Baltimore, MD, United States - Author
Hosp Llobregat, Inst Catala Oncol, Canc Epidemiol Res Programme, Unit Infect & Canc UNIC,IDIBELL, Barcelona 08908, Spain - Author
Hosp Llobregat, Inst Catala Oncol, Serv Hematol, Barcelona, Spain - Author
Hosp Verge Cinta, Serv Anat Patol, IISPV, Tarragona, Spain - Author
Johns Hopkins Univ, Sch Med, Dept Pediat, Stanley Div Dev Neurovirol, Baltimore, MD 21205 USA - Author
Servei d'Anatomia Patològica, Hospital Verge de la Cinta, IISPV, Tortosa, Tarragona, Spain - Author
Servei d'Hematologia, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain - Author
See more

Abstract

Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain.Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95% confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded.MCV seroprevalence was 82% in controls and 85% in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4%; OR = 6.1, 95%CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL.The association observed between serologic evidence of MCV exposure and DLBCL warrants further research.MCV might be involved in the pathway of DLBCL and other lymphomas.©2012 AACR

Keywords

bk viruscarcinomaimmunodeficiencyinfectionjc virusmalignant-lymphomamcvsimian-virus-40t-antigenAdolescentAdultAgedAged, 80 and overAntibodies, viralAntibody responseArticleB cell lymphomaCancer incidenceCapsid proteinsCase-control studiesChronic lymphatic leukemiaChronic lymphocytic-leukemiaControlled studyEnzyme linked immunosorbent assayFemaleFollicular lymphomaHodgkin diseaseHumanHumansImmune deficiencyIncidental findingsLymphomaLymphoma, large b-cell, diffuseMajor clinical studyMaleMerkel cell polyomavirusMerkel cell tumorMiddle agedPriority journalProtein vp1SeroprevalenceSpainT cell lymphomaVirus antibodyVirus like agentWaldenstroem macroglobulinemia

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancer Epidemiology Biomarkers & Prevention due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2012, it was in position 10/161, thus managing to position itself as a Q1 (Primer Cuartil), in the category Public, Environmental & Occupational Health.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.68, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-02, the following number of citations:

  • WoS: 11
  • Scopus: 15
  • Europe PMC: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 28 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: philadelphia; Timor-Leste; United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (ROBLES HELLIN, CLAUDIA) and Last Author (de Sanjos, S).

the author responsible for correspondence tasks has been ROBLES HELLIN, CLAUDIA.